 |
Meeting MicAuthor: Healio
While annual major scientific meetings are the venue to stay up-to-date in your clinical area, it is near impossible to attend all breaking news sessions. Through interviews with experts, Healio's Meeting Mic provides a post-meeting wrap-up of the most important content that listeners can consume on-the-go. Language: en Genres: Health & Fitness, Life Sciences, Medicine, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Highlights from AAO 2026
Episode 34
Monday, 2 November, 2026
In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology annual meeting. In an interview, David R.P. Almeida, MD, MBA, PhD, presented the findings of the phase 4 SYNCHRONICITY study of fluocinolone acetonide intravitreal implant 0.18 mg in patients with noninfectious uveitis affecting the posterior segment. Ali Tafreshi, CEO of Oku, talks about how they will use a network of more than 10,000 healthcare locations for early disease detection through routine eye exams and how their primary goal is to use this emerging field to address the healthcare cost crisis in the U.S. and globally. Next, Jay S. Pepose, MD, PhD, discusses how determining the dominant eye should be one part of monovision planning but not the deciding rule on eye assignment. Dilraj Grewal, MD, highlights phase 2 and phase 3 data in age-related macular degeneration. He also discusses subretinal and intravitreal delivery of gene therapy in neovascular AMD and potentially in geographic atrophy. And, Sunir J. Garg, MD, FACS, FASRS, discusses what has been learned from phase 3 data on two FDA-approved treatments for geographic atrophy. Read the full coverage here: Fluocinolone 0.18 mg has sustained improvements in noninfectious posterior segment uveitis Oku Digital Health uses eye care to detect diseases earlier Monovision planning not always tied to eye dominance Continued development may fulfill unmet needs in retina Early use of geographic atrophy drugs provides longer protection of vision
